Drugs / REC-3964
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06536465 | Oct 2024 → May 2025 | Clostridium difficile colitis | Recursion Pharmaceuticals Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REC-3964 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06536465 ↗ |
| Route | Oral | “This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12...” NCT06536465 ↗ |